Patents by Inventor Philippe DAULL

Philippe DAULL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20230320979
    Abstract: An oil-in-water emulsion for intravitreal administration, especially injection, including an active ingredient, an oil, a mixture of two non-ionic surfactants and water, the emulsion having a droplet size ranging from about 100 to about 200 nm. The emulsion avoids troubles of vision after administration into the vitreous body. The emulsion provides good therapeutic activity of the active ingredient for treating eye diseases or conditions, such as an eye disease or condition of the posterior segment of the eye.
    Type: Application
    Filed: September 15, 2021
    Publication date: October 12, 2023
    Applicant: SANTEN SAS
    Inventors: Mathieu SCHMITT, Philippe DAULL, Jean-Sébastien GARRIGUE
  • Polysaccharides for the treatment of ocular conditions
    Patent number: 11452739
    Abstract: The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 Cobetia marina bacterial strain in ocular conditions associated with ophthalmic dryness and ophthalmic inflammation.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: September 27, 2022
    Assignee: SANTEN SAS
    Inventors: Jennifer Dourlat, Philippe Daull, Jean-Sébastien Garrigue
  • GENE SIGNATURE FOR THE PROGNOSIS OF DRY EYE DISEASE
    Publication number: 20220098669
    Abstract: Disclosed is a signature including at least 3 markers, as well as a method for the prognosis of dry eye disease in a subject, wherein the method includes assessing the expression of markers of a signature in a sample from the subject. Also disclosed is a kit for implementing this method.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 31, 2022
    Inventors: Christophe BAUDOUIN, Philippe DAULL, Karima KESSAL
  • POLYSACCHARIDES FOR THE TREATMENT OF OCULAR CONDITIONS
    Publication number: 20210106610
    Abstract: The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 Cobetia marina bacterial strain in ocular conditions associated with ophthalmic dryness and ophthalmic inflammation.
    Type: Application
    Filed: March 26, 2019
    Publication date: April 15, 2021
    Applicant: SANTEN SAS
    Inventors: Jennifer DOURLAT, Philippe DAULL, Jean-Sébastien GARRIGUE
  • GENE SIGNATURE FOR THE PROGNOSIS OF DRY EYE DISEASE
    Publication number: 20190093165
    Abstract: Disclosed is a signature including at least 3 markers, as well as a method for the prognosis of dry eye disease in a subject, wherein the method includes assessing the expression of markers of a signature in a sample from the subject. Also disclosed is a kit for implementing this method.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Inventors: Christophe BAUDOUIN, Philippe DAULL, Karima KESSAL
  • Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
    Patent number: 9555045
    Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: January 31, 2017
    Assignee: SANTEN SAS
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
  • Use of prostaglandins F2Alpha and analogues for the healing of corneal and conjunctival lesions
    Patent number: 9072750
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: July 7, 2015
    Assignee: SANTEN SAS
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
  • Use of Prostaglandins F2Alpha and Analogues for the Healing of Corneal and Conjunctival Lesions
    Publication number: 20120225939
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Application
    Filed: November 19, 2010
    Publication date: September 6, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
  • USE OF PROSTAGLANDINS F2ALPHA AND ANALOGUES FOR THE HEALING OF CORNEAL AND CONJUNCTIVAL LESIONS
    Publication number: 20110118349
    Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 19, 2011
    Applicant: NOVAGALI PHARMA S.A.
    Inventors: Jean-Sébastien GARRIGUE, Frédéric LALLEMAND, Philippe DAULL, Christophe BAUDOUIN